BIRC5 and neoplasm: More recently, treatment of MDA-MB-231 breast cancer cells with paclitaxel has been shown to trigger the secretion of survivin-enriched EVs that can modulate the resistance of the tumor not only to the drug itself but also to other stressful conditions, such as serum starvation [39].